Get the Stockscreener App
2.225
6.12%
-0.145
Codexis Inc stock is traded at $2.225, with a volume of 412.42K.
It is down -6.12% in the last 24 hours and down -12.40% over the past month.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
See More
Previous Close:
$2.37
Open:
$2.38
24h Volume:
412.42K
Relative Volume:
0.49
Market Cap:
$200.85M
Revenue:
$70.14M
Net Income/Loss:
$-76.24M
P/E Ratio:
-2.0045
EPS:
-1.11
Net Cash Flow:
$-57.06M
1W Performance:
-14.42%
1M Performance:
-12.40%
6M Performance:
-11.71%
1Y Performance:
-36.43%
1-Day Range:
$2.22
$2.38
1-Week Range:
$2.22
$2.73
52-Week Range:
$1.90
$6.08
Codexis Inc Stock (CDXS) Company Profile
Name
Codexis Inc
Sector
Industry
Phone
650-421-8100
Address
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
2.225 | 213.93M | 70.14M | -76.24M | -57.06M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.56 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.11 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.09 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.14 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.19 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-03-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-29-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-07-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-07-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Apr-12-21 | Initiated | Piper Sandler | Overweight |
| Mar-01-21 | Initiated | Stifel | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-10-20 | Initiated | The Benchmark Company | Buy |
| Jan-17-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| May-16-18 | Initiated | Stephens | Overweight |
| Oct-13-17 | Reiterated | H.C. Wainwright | Buy |
| May-31-17 | Initiated | Jefferies | Buy |
| Jan-26-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Jan-04-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-06-16 | Initiated | H.C. Wainwright | Buy |
View All
Codexis Inc Stock (CDXS) Latest News
Can volume confirm reversal in Codexis Inc.Market Performance Summary & Weekly High Potential Alerts - newser.com
Will Codexis Inc. stock outperform tech sector in 2025Market Growth Report & Reliable Price Action Trade Plans - newser.com
How to escape a deep drawdown in Codexis Inc.IPO Watch & Technical Entry and Exit Tips - newser.com
What MACD signals say about Codexis Inc.2025 Institutional Moves & Accurate Trade Setup Notifications - newser.com
Is Codexis Inc. stock dividend yield sustainable2025 Short Interest & Target Return Focused Stock Picks - newser.com
Is Codexis Inc. meeting your algorithmic filter criteriaEntry Point & Safe Capital Investment Plans - newser.com
Why Codexis Inc. stock is considered a top pickJuly 2025 Opening Moves & Reliable Price Action Trade Plans - newser.com
How Codexis Inc. stock trades before earningsJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
Is Codexis Inc. stock a safe investment in uncertain markets2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
What risks investors should watch in Codexis Inc. stockJuly 2025 PostEarnings & Step-by-Step Swing Trade Plans - newser.com
Is Codexis Inc. forming a reversal patternRecession Risk & AI Forecast Swing Trade Picks - newser.com
How Codexis Inc. stock benefits from strong dollarJuly 2025 Update & AI Forecasted Entry/Exit Points - newser.com
How hedge fund analytics apply to Codexis Inc. stockPortfolio Performance Summary & High Accuracy Buy Signal Tips - newser.com
How to use Fibonacci retracement on Codexis Inc.Quarterly Performance Summary & Low Risk High Win Rate Picks - newser.com
Detecting price anomalies in Codexis Inc. with AIEarnings Trend Report & Long Hold Capital Preservation Plans - newser.com
Strategies to average down on Codexis Inc.Analyst Upgrade & Verified Swing Trading Watchlists - newser.com
Codexis, Inc. $CDXS Position Boosted by Pier Capital LLC - MarketBeat
Will Codexis Inc. stock outperform Dow Jones index2025 AllTime Highs & Accurate Entry/Exit Alerts - newser.com
How to build a dashboard for Codexis Inc. stockNew Guidance & Smart Money Movement Alerts - newser.com
Codexis (NASDAQ:CDXS investor five-year losses grow to 84% as the stock sheds US$29m this past week - simplywall.st
Will Codexis Inc. price bounce be sustainableJuly 2025 Review & Technical Pattern Recognition Alerts - newser.com
How Codexis Inc. stock reacts to oil pricesQuarterly Profit Report & Risk Managed Investment Strategies - newser.com
Can swing trading help recover from Codexis Inc. losses2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's Eco Synthesis®? Manufacturing Platform for Therapeutic siRNA Manufacturing - MarketScreener
Codexis (CDXS) Enters Evaluation Partnership with Nitto Denko Av - GuruFocus
Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing - Yahoo Finance
Codexis Inc Stock (CDXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):